Showing posts with label IPO. Show all posts
Showing posts with label IPO. Show all posts

Thursday, 2 November 2023

Age, Size, and Sectors in IPO Performance: A Comprehensive Analysis | Chapter 10 | An Overview on Business, Management and Economics Research Vol. 4

 This study offers a new perspective on the stock price conduct of firms that went public through IPOs between 2009 and 2019. It tests the impact of their size, age and for-profit businesses on future performance. The analysis surrounds data from 1611 IPOs extending across 11 economic sectors, engaging the event study plan. The findings provide solid evidence that a firm's size and age be a part of predictors for both temporary and long-term price performance. In addition, skilled is a significant alternative in the long-term performance middle from two points sectors and 'tween small and large firms inside each sector, accompanying smaller firms exhibiting more distinct underperformance over time. This wonder can be assign to differences in publicly feasible information, seen risk, and resource availability betwixt older, best firms and their younger, smaller matches. Notably, the study reveals specific sector-distinguishing patterns in the age of firms going public. There is a clear tendency for firms in the healthcare and science sectors to make known at a relatively younger age than those in additional sectors, emphasize the strategic advantages of early IPOs for these rules. These findings hold suggestions for asset pricing and offer valuable acumens for investors busy in IPOs.

Author(s) Details:

Smadar Siev,
School of Business Administration, Ono Academic College; Kiryat Ono 759, Israel.

Please see the link here: https://stm.bookpi.org/AOBMER-V4/article/view/12347

Friday, 19 November 2021

The Role of Market Capitalization and Tweet Volumes in Shaping Investors Behavior Post Biotechnology IPOs | Chapter 14 | New Innovations in Economics, Business and Management Vol. 2

 This research examines the impact of social media, notably Twitter, on stock returns for biotechnology companies after their first public offerings (IPOs). While the risk associated with biotechnology initiatives lessens as the product development cycle progresses, the absolute capital requirements increase. The findings show positive but insignificant cumulative average abnormal returns (CAARs) of 1.97 percent in the first 25 days after the IPO, followed by a drop of tens of percentage points over the next three years. However, when the sample firms are divided into two subsamples based on market value, either under or over USD 500 million, the overall results shift substantially. Companies with a market capitalization of less than USD 500 million have negative CAARs right after the IPO, but this negative CAAR becomes substantial only around day 50. Firms with a market value of more than USD 500 million have positive CAARs right after the IPO, which become significant by day 50 and stay that way for the rest of the year. These findings can be explained by the short attention span of investors, which grows until the end of the quiet period and then declines in the post-IPO years for small businesses. An analysis of Twitter activity and stock returns reveals a strong link between the two, implying that investors' interest in companies is mirrored in their Twitter usage.


Author(S) Details

Smadar Siev
Faculty of Business Administration, Haifa Campus Port Gate Building, Ono Academic College, HaNamal 32, Haifa 3303201, Israel.

View Book:- https://stm.bookpi.org/NIEBM-V2/article/view/4750